Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Kümmel S, Burchardi N, von Minckwitz G, Fasching P, Klare P, Engels K, Denkert C, Schneeweiss A, Jackisch C, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Blohmer J, Untch M, Schem C, Huober J, Paepke S, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer 2017; 84:1-8.
30.07.2017Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
30.07.2017Eur J Cancer 2017; 84:1-8
Kümmel Sherko, Burchardi Nicole, von Minckwitz Gunter, Fasching Peter A, Klare Peter, Engels Knut, Denkert Carsten, Schneeweiss Andreas, Jackisch Christian, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Blohmer Jens Uwe, Untch Michael, Schem Christian, Huober Jens, Paepke Stefan, Loibl Sibylle
Unilateral tongue myokymia - A rare topodiagnostic sign of different clinical conditions
Leupold D, Schilg-Hafer L, Felbecker A, Kim O, Tettenborn B, Hundsberger T. Unilateral tongue myokymia - A rare topodiagnostic sign of different clinical conditions. J Clin Neurosci 2017
29.07.2017Unilateral tongue myokymia - A rare topodiagnostic sign of different clinical conditions
29.07.2017J Clin Neurosci 2017
Leupold Daniela, Schilg-Hafer Lenka, Felbecker Ansgar, Kim Olaf Chan-Hi, Tettenborn Barbara, Hundsberger Thomas
Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland.
Glier H, Heijnen I, Hauwel M, Dirks J, Quarroz S, Lehmann T, Rovó A, Arn K, Matthes T, Hogan C, Keller P, Dudkiewicz E, Stussi G, Fernandez P, ĀăąĆĉČĎ Ā. Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. J Immunol Methods 2017; 475:112348.
29.07.2017Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland.
29.07.2017J Immunol Methods 2017; 475:112348
Glier Hana, Heijnen Ingmar, Hauwel Mathieu, Dirks Jan, Quarroz Stéphane, Lehmann Thomas, Rovó Alicia, Arn Kornelius, Matthes Thomas, Hogan Cassandra, Keller Peter, Dudkiewicz Ewa, Stussi Georg, Fernandez Paula, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
28.07.2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
28.07.2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection
Gueller U, Warschkow R, Ackermann C, Schmied B, Cerny T, ess s. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. Swiss Med Wkly 2017; 147:w14473.
27.07.2017Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection
27.07.2017Swiss Med Wkly 2017; 147:w14473
Gueller Ulrich, Warschkow Rene, Ackermann Christoph Jakob, Schmied Bruno, Cerny Thomas, ess silvia
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
24.07.2017Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
24.07.2017Lung Cancer 2017; 111:176-181
Diem Stefan, Schmid Sabine, Krapf Mirjam, Flatz Lukas, Born Diana, Jochum Wolfram, Templeton Arnoud J, Früh Martin
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome
Fischer A, Bastian S, Cogliatti S, Mey U, Saub J, Schanz U, Padberg S, Hohloch K. Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome. Hematol Oncol 2017
06.07.2017Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome
06.07.2017Hematol Oncol 2017
Fischer Angela, Bastian Sara, Cogliatti Sergio B., Mey Ulrich, Saub Jenny, Schanz Urs, Padberg Sgier, Hohloch Karin
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
05.07.2017Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
05.07.2017Leukemia 2017; 32:391-401
Besse Andrej, Besse Lenka, Overkleeft H S, Bader J, Kraus Marianne, Morgan G J, Weinhold N, Rasche L, Stolze S C, Driessen Christoph
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Riethdorf S, Untch M, von Minckwitz G, Schem C, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Weber K, Nekljudova V, Loibl S, Müller V, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res 2017; 23:5384-5393.
05.07.2017Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
05.07.2017Clin Cancer Res 2017; 23:5384-5393
Riethdorf Sabine, Untch Michael, von Minckwitz Gunter, Schem Christian, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Weber Karsten, Nekljudova Valentina, Loibl Sibylle, Müller Volkmar, Pantel Klaus
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Untch M, Luftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Kühn T, Janni W, Gerber B, Huober J, Jackisch C, Schneeweiss A, Brucker S, Dall P, Denkert C, Fasching P, Fehm T, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd 2017; 77:633-644.
28.06.2017Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
28.06.2017Geburtshilfe Frauenheilkd 2017; 77:633-644
Untch Michael, Luftner Diana, Möbus Volker, Müller Volkmar, Rody Achim, Sinn Peter, Thill Marc, Thomssen Christoph, Harbeck Nadia, Kühn Thorsten, Janni Wolfgang, Gerber Bernd, Huober Jens, Jackisch Christian, Schneeweiss Andreas, Brucker Sara Y, Dall Peter, Denkert Carsten, Fasching Peter A, Fehm Tanja, Liedtke Cornelia
Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial
Vehoff J, Hägele-Link S, Humm A, Müller S, Sauter R, Tettenborn B, Hundsberger T (2017). Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial.
25.06.2017Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial
25.06.20173rd EAN Congress
Vehoff Jochen, Hägele-Link Stefan, Humm Andrea, Müller Stefanie, Sauter Rafael, Tettenborn Barbara, Hundsberger Thomas
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Omlin A, Ryan C, Rubin M, Roach M, Pritchard C, Parker C, Padhani A, Ost P, Oh W, Murthy V, Mottet N, Morris M, Morgans A, Maluf F, Saad F, Sartor O, Wiegel T, Valdagni R, Tombal B, Tannock I, Sydes M, Sweeney C, Suzuki H, Sternberg C, Soule H, Smith M, Shore N, Sella A, Scher H, Logothetis C, Kramer G, Khauli R, Dos Reis R, de Bono J, Davis I, Daugaard G, Clarke N, Chung B, Castellano D, Carver B, Bristow R, Bossi A, Beltran H, Beer T, Attard G, Drake C, Eeles R, Kellokumpu-Lehtinen P, Kantoff P, James N, Higano C, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Feng F, Fanti S, Evans C, Efstathiou E, Gillessen Sommer S. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2017
24.06.2017Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
24.06.2017Eur Urol 2017
Omlin Aurelius, Ryan Charles, Rubin Mark A, Roach Mack, Pritchard Colin C, Parker Chris, Padhani Anwar R, Ost Piet, Oh William, Murthy Vedang, Mottet Nicolas, Morris Michael J, Morgans Alicia K, Maluf Fernando, Saad Fred, Sartor Oliver, Wiegel Thomas, Valdagni Riccardo, Tombal Bertrand, Tannock Ian, Sydes Matthew R, Sweeney Christopher, Suzuki Hiroyoshi, Sternberg Cora N, Soule Howard, Smith Matthew, Shore Neal, Sella Avishay, Scher Howard, Logothetis Chris, Kramer Gero, Khauli Raja B, Dos Reis Rodolfo Borges, de Bono Johann, Davis Ian D, Daugaard Gedske, Clarke Noel, Chung Byung Ha, Castellano Daniel, Carver Brett, Bristow Rob, Bossi Alberto, Beltran Himisha, Beer Tomasz M, Attard Gerhardt, Drake Charles G, Eeles Ros, Kellokumpu-Lehtinen Pirkko-Liisa, Kantoff Philip, James Nicolas, Higano Celestia S, Heidenreich Axel, Halabi Susan, Gleave Martin, Frydenberg Mark, Fizazi Karim, Feng Felix, Fanti Stefano, Evans Christopher P, Efstathiou Eleni, Gillessen Sommer Silke
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
19.06.2017Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
19.06.2017Basic Clin Pharmacol Toxicol 2017; 121:309-315
Parra-Guillen Zinnia P, Kloft Charlotte, Krähenbühl Stephan, Gillessen Sommer Silke, Früh Martin, Pfister Bogumila, Winogradova Daria, Donzelli Massimiliano, Haschke Manuel, Berger Peter B, Jörger Markus
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.
Meyer S, Steinmann E, Lehmann T, Muesser P, Passweg J, Skoda R, Tsakiris D. Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. Biomed Res Int 2017; 2017:9876819.
18.06.2017Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.
18.06.2017Biomed Res Int 2017; 2017:9876819
Meyer Sara C, Steinmann Eva, Lehmann Thomas, Muesser Patricia, Passweg Jakob R, Skoda Radek C, Tsakiris Dimitrios A
The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis
Vagnildhaug O, Solheim T, Laird B, Kaasa S, Hjermstad M, Baracos V, Strasser F, Fayers P, Wilcock A, Blum D. The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis. J Cachexia Sarcopenia Muscle 2017
18.06.2017The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis
18.06.2017J Cachexia Sarcopenia Muscle 2017
Vagnildhaug Ola Magne, Solheim Tora S, Laird Barry, Kaasa Stein, Hjermstad Marianne J, Baracos Vickie E, Strasser Florian, Fayers Peter, Wilcock Andrew, Blum David
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematol Oncol 2017
16.06.2017Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
16.06.2017Hematol Oncol 2017
Gobba Stefania, Gaidano Gianluca, Pinotti Graziella, Hitz Felicitas, Stathis Anastasios, Aprile von Hohenstaufen Kathrin, Margiotta-Casaluci Gloria, Iacoboni Gloria, Cascione Luciano, Diem Stefan, Conconi Annarita, Gulden-Sala Wiebke, Moccia Alden A, Zucca Emanuele
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Peters S, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Früh M, Ho C, Gettinger S, Johnson M, Jänne P, Garassino M, Christoph D, Toh C, Rizvi N, Chaft J, Carcereny Costa E, Patel J, Chow L, Koczywas M, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017; 35:2781-2789.
13.06.2017Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
13.06.2017J Clin Oncol 2017; 35:2781-2789
Peters Solange, van den Heuvel Michel, Rothenstein Jeffrey, Reck Martin, Paz-Ares Luis, Shepherd Frances A, Kurata Takayasu, Li Zhengrong, Qiu Jiaheng, Kowanetz Marcin, Mocci Simonetta, Shankar Geetha, Sandler Alan, Früh Martin, Ho Cheryl, Gettinger Scott, Johnson Melissa L, Jänne Pasi A, Garassino Marina C, Christoph Daniel, Toh Chee Keong, Rizvi Naiyer A, Chaft Jamie E, Carcereny Costa Enric, Patel Jyoti D, Chow Laura Q M, Koczywas Marianna, Felip Enriqueta
Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Henrich A, Jörger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362:347-358.
09.06.2017Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
09.06.2017J Pharmacol Exp Ther 2017; 362:347-358
Henrich Andrea, Jörger Markus, Kraff Stefanie, Jaehde Ulrich, Huisinga Wilhelm, Kloft Charlotte, Parra-Guillen Zinnia Patricia
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
Siano M, Frattini M, Ghielmini M, Corradino I, Freguia S, Früh M, Mach N, Martin V, Molinari F, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. Oncologist 2017
07.06.2017Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
07.06.2017Oncologist 2017
Siano Marco, Frattini Milo, Ghielmini Michele, Corradino Irene, Freguia Stefania, Früh Martin, Mach Nicolas, Martin Vittoria, Molinari Francesca, Espeli Vittoria
Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study
Weixler B, Viehl C, Warschkow R, Gueller U, Ramser M, Sauter R, Zuber M. Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study. JAMA Surg 2017
07.06.2017Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study
07.06.2017JAMA Surg 2017
Weixler Benjamin, Viehl Carsten T, Warschkow Rene, Gueller Ulrich, Ramser Michaela, Sauter Rafael, Zuber Markus